Home › Research › Costs and economics
Cost-effectiveness of treatments for Alzheimer's dementia
Anders Wimo, Anders Norlund. Expert review of pharmacoeconomics & outcomes research, 2007-02
Topic: Drug trials: efficacy and safety
Plain-language summary
Care of dementia is extremely resource demanding and has a great impact on both the formal care systems and the situation for informal carers. Thus, the question of cost-effectiveness is crucial. This presentation is, to a great extent, based on the dementia project by the Swedish council on technology assessment in health care. After the database search and quality judgment of papers, 22 papers of drug treatment were finally included. A summary of the situation as regards cost-effectiveness on drugs for Alzheimer's disease showed that no evidence could be stated on empirical studies. Although most modeling studies indicate cost-effectiveness, this was not regarded as enough support for cost-effectiveness since the empirical studies were inconclusive. The need for larger empirical studies of high standards of quality and modeling studies including an enlarged sensitivity analysis, is evident.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wimo, A., & Norlund, A. (2007). Cost-effectiveness of treatments for Alzheimer's dementia. Expert review of pharmacoeconomics & outcomes research. https://doi.org/10.1586/14737167.7.1.83
Vancouver
Wimo A, Norlund A. Cost-effectiveness of treatments for Alzheimer's dementia. Expert review of pharmacoeconomics & outcomes research. 2007. doi:10.1586/14737167.7.1.83. PMID: 20528433.
BibTeX
@article{wimo2007-20528433,
author = {Wimo, Anders and Norlund, Anders},
title = {{Cost-effectiveness of treatments for Alzheimer's dementia}},
journal = {Expert review of pharmacoeconomics \& outcomes research},
year = {2007},
doi = {10.1586/14737167.7.1.83},
pmid = {20528433},
url = {https://doi.org/10.1586/14737167.7.1.83}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- A summary of the situation as regards cost-effectiveness on drugs for Alzheimer's disease showed that no evidence could be stated on empirical studies.
New to this subject? Start with our plain-English guide: Costs & economics →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 21 of the 56 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert review of pharmacoeconomics & outcomes research) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2007 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 20528433) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 21 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 21 of the 56 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Costs and economics from nearby years
Also tagged “cholinesterase”
272 studies in the library carry the topic tag “cholinesterase”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 272 tagged studies.